Notice: wpdb::prepare was called incorrectly. The query does not contain the correct number of placeholders (2) for the number of arguments passed (3). Please see Debugging in WordPress for more information. (This message was added in version 4.8.3.) in /webspace/12/53461/ on line 3942
VAXIMM company portrait | VAXIMM


VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors.

VAXIMM completed a Phase I/II trial of VXM01 in advanced pancreatic cancer. Clinical trials are completed or ongoing in metastatic colorectal cancer and in recurrent glioblastoma (brain cancer).

The Company has several additional product candidates at various stages of preclinical development. These candidates can be developed as stand-alone therapies or in combination with other immunotherapies, including VXM01.

Investors in our company include: BB Biotech Ventures, Merck Serono Ventures, Sunstone Capital and BioMed Partners.

VAXIMM AG is headquartered in Basel, Switzerland with a wholly owned subsidiary, VAXIMM GmbH (Mannheim, Germany), from where the Company’s development activities are orchestrated, and a laboratory in Regensburg, Germany.

Management Team

VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise.

Matthias Schroff, PhD
Chief Executive Officer
Matthias Schroff joined VAXIMM as CEO in September 2016. He has over fifteen years of experience in the biotechnology industry. Previously, he was CEO of Mologen AG, a publicly traded German biotech company, serving on the company’s executive board for over ten years. In the eight years that Dr. Schroff served as CEO, he built Mologen from an early preclinical stage to an established immuno-oncology company with programs in Phase 2 and 3 clinical trials. In addition to his position at Mologen, Dr. Schroff served on the Board of Directors of the biotech arm of the Association of Research-based Pharmaceutical Companies (vfA bio). During his career, Dr. Schroff has served in a variety of functions, including research, manufacturing, scientific collaborations, for example with the MD Anderson Cancer Center, clinical development, business development and investor relations. He is the inventor of numerous patents in the field of immuno-oncology, RNAi and gene expression, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications. Dr. Schroff received his PhD in biochemistry from Freie Universität Berlin at the Institute of Molecular Biology and Biochemistry, where he was involved in clinical trials in immunotherapy against cancer as early as 1994.
Heinz Lubenau, PhD
Chief Operating Officer
Heinz Lubenau co-founded VAXIMM in 2008. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, where he led the development work of the first biosimilar G-CSF Ratiograstim® from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2. In 1994 he joined Servier Forschung und Pharmaentwicklung GmbH as Junior Project leader and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. In this role he was responsible for Servier Phase 1 to Phase 3 clinical trials in Germany, Austria and Switzerland for cardiology, diabetes and hypertension, including the registration trials of Preterax® and Procoralan®. At this time, he also led clinical project teams and was responsible for hiring clinical project staff. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.
Marc Mansour, PhD, MBA
Chief Business Officer
Marc Mansour joined VAXIMM in September 2016 with over 15 years of experience in biotech R&D and management. He was previously with Immunovaccine, Inc., a publicly traded Canadian company focused on developing cancer immunotherapies and infectious disease vaccines, for thirteen years. There, he served in positions of increasing responsibility, including Chief Scientific Officer, and, ultimately, Chief Executive Officer. He has strong expertise in vaccines and the early clinical development of immuno-oncology products. He has published a number of articles in peer-reviewed journals and holds several patents. Dr. Mansour has a PhD in biology from Dalhousie University and an MBA from the Sobey School of Business.

Supervisory Board

Thomas Hecht, MD
Thomas Hecht, MD, Chairman, is a seasoned manager and has extensive experience in the biopharmaceutical industry. Dr. Hecht is founder and owner of Hecht Healthcare Consulting, which provides marketing, clinical development and mergers & acquisitions services to the pharmaceutical/biotechnology industry. Previously, he was VP Marketing (Hematology, Oncology, New Products) at Amgen Europe. Before that, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen Europe. He currently serves as Chairman of the Boards of Affimed N.V., Cell Medica Ltd. and Aelix Therapeutics S.L.. He was previously Chairman of the Boards of ESBATech AG (acquired by Alcon/Novartis in 2009), SuppreMol GmbH (acquired by Baxalta in 2015) and Cytos AG and Member of the Board of Humabs BioMed AG . Prior to joining the biopharmaceutical industry, Dr. Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Klaus Breiner, PhD
Klaus Breiner, PhD, Vice-Chairman is a Managing Partner at BB BIOTECH VENTURES. He co-founded VAXIMM and served as its Executive Chairman until 2016. Over the last two decades, Dr. Breiner has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology (ETH) in Zurich and at the Center for Molecular Biology in Heidelberg (ZMBH). Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg. Dr. Breiner’s past and present board assignments include Agendia BV, AM-Pharma BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc. (now publicly listed), Glycart Biotechnology AG (acquired by Roche), Natural Dental Implants AG and Orthocon Inc.
Mathieu Simon, MD
Mathieu Simon, MD is Executive Vice President, Chief Operating Officer of Cellectis (NASDAQ: CLLS), one of the biopharmaceutical companies leading the development of CAR-T cell immunotherapies. He has been a member of the Cellectis Board of Directors since 2013. Prior to joining Cellectis, he was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre SA. From 1994 to 2010, Dr. Simon served at Wyeth Pharmaceuticals in both senior corporate and regional roles in the US and Europe (Head of International Marketing and Medical Affairs and Managing Director of several Wyeth affiliates). Dr. Simon is an advisor to the European Commission D.G. Research and Innovation. He also serves as Senior Strategic Advisor to Messier Maris Partners, an international investment banking boutique. Dr. Simon was certified in internal medicine at the Faculty of Medicine, Paris VII.
Bram Vanparys, PhD, MBA
Bram Vanparys, PhD, MBA, is a Director at Merck Ventures. He joined the previous biopharma fund – MS Ventures – in 2015 as Investment Director. Between 2010 and 2015, he was senior investment manager life sciences at PMV (Brussels, Belgium), where he built the biotech franchise. He was instrumental in the start-up, growth and exit of several biotech companies. Before PMV, Bram Vanparys was biotech analyst at KBC Private Equity and consultant at Deloitte. He holds a PhD in biotechnology from the University of Ghent, Belgium and an MBA from Vlerick Business School, Belgium.
Patrick Burgermeister
Patrick Burgermeister joined BioMedPartners in 2006, coming from Novartis where he was Senior Portfolio Manager of project management. There, he was responsible for the evaluation and prioritization of development projects from preclinical to registration stage. Prior to Novartis, he was Senior Financial Analyst responsible for the European Biotech and Pharma sector at Zürcher Kantonalbank. In addition, he served as advisor to the healthcare fund Pharma Vision. Before that, he worked as strategic planning manager at Jomed AG (now Abbott Vascular). Mr. Burgermeister headed the business development at Apeiron Biologics (Vienna, Austria) where he was instrumental in several licensing deals. He also served as chairman of a dermatology startup and is board member of the business angel club BioBAC. Mr. Burgermeister holds master’s degrees in molecular biology from the University of Basel (Biozentrum) and in business administration from the University of St. Gallen (HSG). He is a Chartered Financial Analyst (CFA).
Jean-Paul Prieels, PhD
Jean-Paul Prieels, PhD served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. Dr. Prieels joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development. He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He served as Head of Research at GSK Vaccines. He serves as a member of the Independent Advisory Board for Curavac Inc. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as Chairman of the Board at Immune Health and he was also a Board member of Henogen from 2000 to 2008 (today Novasep).
Sten Verland, PhD
Sten Verland, PhD is a partner in the Life Science group and one of the three co-founders of Sunstone. Dr. Verland focuses on therapeutics investments. During his career, he has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. While at Sunstone, Dr. Verland has played a key role in executing two exits (Action Pharma and Zymenex). Both deals made it to the global Top Ten list of published upfront cash deals in 2007-2012. He holds a master’s degree in biology and mathematics and a PhD in immunology – both from the University of Copenhagen. Dr. Verland serves as a board member of the Danish Venture Capital Association.


If you are considering joining a dynamic life sciences company, working with cutting edge science to combat cancer, and wish to know more about the opportunities with VAXIMM, please send your resume and cover letter through the form below or contact us at

Your Name (required)

Your E-Mail (required)


Resume (max. 3MB, PDF)

Cover Letter (max. 3MB, PDF)

Your Message